In this issue:
Efficacy and safety of remibrutinib
Association between CSU and atopic comorbidities
Update and clinical overview of urticaria-like dermatoses during pregnancy
Comparing characteristics, immunologic parameters and treatment outcomes between NSAID exacerbated CSU and NSAID tolerant CSU
Pathologic role of IL-17
Gut microbes and CSU risk
Omalizumab versus dupilumab
Characteristics of CSU subtypes
Tofacitinib for CSU patients with suboptimal responses to omalizumab
Gender-specific differences in response to omalizumab
Please login below to download this issue (PDF)